Phase I study of single‐agent ribociclib in Japanese patients with advanced solid tumors

The cyclin D‐CDK4/6‐INK4‐Rb pathway is frequently dysregulated in cancers. Ribociclib, an orally available, selective CDK4/6 inhibitor, showed preliminary clinical activity in a phase I study in the USA and Europe for patients with solid tumors and lymphomas. The present study aimed to determine the...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Hewes, Becker, Kakizume, Tomoyuki, Tajima, Takeshi, Ishikawa, Norifumi, Yamada, Yasuhide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765307/
https://www.ncbi.nlm.nih.gov/pubmed/29059492
http://dx.doi.org/10.1111/cas.13428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765307/
https://www.ncbi.nlm.nih.gov/pubmed/29059492
http://dx.doi.org/10.1111/cas.13428

Ejemplares similares